MedTrace Logo

Study Evaluating Single Ascending Doses of MR1817

NCT00960180 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2014-01-13

No results posted yet for this study

Summary

This is a first-in-human study of MR1817. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MR1817 after administration of ascending single oral doses to healthy adult subjects.

Conditions

  • Adult

Interventions

DRUG

MR1817

DRUG

Placebo

Sponsors & Collaborators

  • Mochida Pharmaceutical Company, Ltd.

    lead INDUSTRY

Principal Investigators

  • Robert Miller · Fulcrum Pharma (Europe) Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00960180 on ClinicalTrials.gov